Literature DB >> 7594682

Quantitative measures of human immunodeficiency virus-specific antibodies predict progression to AIDS.

S A Strathdee1, J W Frank, J McLaughlin, M Leblanc, C Major, M V O'Shaughnessy, S E Read.   

Abstract

Studies examining specific antibodies directed against antigenic components of human immunodeficiency virus (HIV), as potential markers of progression to AIDS, have reported inconsistent results. We used reflectance densitometry and survival analysis to determine whether single quantitative measures of HIV-specific antibodies predicted progression to AIDS in a prospective cohort of 159 HIV-infected homosexual men. Lowered baseline levels of p24 antibody and p24/gp41 antibody ratio were independent predictors of progression to AIDS and retained statistical significance after simultaneously controlling for CD4:CD8 ratio, age, use of zidovudine, and clinical symptoms. Quantitative measures of p24 antibody and p24/gp41 antibody ratio warrant further study with regards to their clinical application as markers of HIV disease progression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594682     DOI: 10.1093/infdis/172.5.1375

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

1.  Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS.

Authors:  E L Delwart; H Pan; H W Sheppard; D Wolpert; A U Neumann; B Korber; J I Mullins
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections.

Authors:  K S Cole; M Murphey-Corb; O Narayan; S V Joag; G M Shaw; R C Montelaro
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

3.  Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1.

Authors:  J M Binley; P J Klasse; Y Cao; I Jones; M Markowitz; D D Ho; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

4.  Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.

Authors:  R I Connor; D C Montefiori; J M Binley; J P Moore; S Bonhoeffer; A Gettie; E A Fenamore; K E Sheridan; D D Ho; P J Dailey; P A Marx
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

5.  Delivering HIV Gagp24 to DCIR Induces Strong Antibody Responses In Vivo.

Authors:  Anne-Laure Flamar; Vanessa Contreras; Sandra Zurawski; Monica Montes; Nathatlie Dereuddre-Bosquet; Frédéric Martinon; Jacques Banchereau; Roger Le Grand; Gerard Zurawski; Yves Levy
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

6.  The intraspleen huPBL NOD/SCID model to study the human HIV-specific antibody response selected in the course of natural infection.

Authors:  Sophia Steyaert; Lieven Verhoye; Els Beirnaert; Helen Donners; Katrien Fransen; Leo Heyndrickx; Guido Vanham; Geert Leroux-Roels; Peter Vanlandschoot
Journal:  J Immunol Methods       Date:  2007-01-09       Impact factor: 2.303

7.  T cell independent secondary antibody responses to the envelope protein of simian immunodeficiency virus.

Authors:  Ghulam Nabi; Vladimir Temchura; Claudius Grossmann; Seraphin Kuate; Matthias Tenbusch; Klaus Überla
Journal:  Retrovirology       Date:  2012-05-14       Impact factor: 4.602

8.  The Cancer-Associated Virus Landscape in HIV Patients with Oral Hairy Leukoplakia, Kaposi's Sarcoma, and Non-Hodgkin Lymphoma.

Authors:  Peter D Burbelo; Joseph A Kovacs; Jason Wagner; Ahmad Bayat; Craig S Rhodes; Yvonne De Souza; John S Greenspan; Michael J Iadarola
Journal:  AIDS Res Treat       Date:  2012-08-08

9.  HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy.

Authors:  L Morris; J M Binley; B A Clas; S Bonhoeffer; T P Astill; R Kost; A Hurley; Y Cao; M Markowitz; D D Ho; J P Moore
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.